Supernus Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Supernus Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Supernus Pharmaceuticals Inc Strategy Report
- Understand Supernus Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Supernus Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
US20220233548A1 | Application | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | A61K31/00; A61K31/5375 | July 28, 2022 |
US20220211641A1 | Application | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE | A61K31/13; A61K31/197; A61K31/198; A61K45/06; A61K9/0004; A61K9/0053; A61K9/16; A61K9/1617; A61K9/1652; A61K9/2009; A61K9/2054; A61K9/2846; A61K9/4808; A61K9/5021; A61K9/5047; A61K9/5078 | July 07, 2022 |
EP3624779A4 | Search Report | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON HUPERZIN MIT MODIFIZIERTER FREISETZUNG UND VERFAHREN ZUR VERWENDUNG DAVON | A61K31/435; A61K31/4748; A61K47/32; A61K47/38; A61K9/48; A61K9/4866; A61K9/5042; A61K9/5047; A61K9/5078; A61P25/08 | July 06, 2022 |
US11351120B2 | Grant | Use of higher doses of modified release huperzine formulations | A61K31/439; A61K9/1676; A61P25/08 | June 07, 2022 |
US11324753B2 | Grant | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | A61K31/00; A61K31/5375 | May 10, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer